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Abstract
Background: The epigenome plays a key role in cancer heterogeneity and drug resistance. Hence, a number of
epigenetic inhibitors have been developed and tested in cancers. The major focus of most studies so far has been
on the cytotoxic effect of these compounds, and only few have investigated the ability to revert the resistant
phenotype in cancer cells. Hence, there is a need for a systematic methodology to unravel the mechanisms behind
epigenetic sensitization.
Results: We have developed a high-throughput protocol to screen non-simultaneous drug combinations, and used
it to investigate the reprogramming potential of epigenetic inhibitors. We demonstrated the effectiveness of our
protocol by screening 60 epigenetic compounds on diffuse large B-cell lymphoma (DLBCL) cells. We identified
several histone deacetylase (HDAC) and histone methyltransferase (HMT) inhibitors that acted synergistically with
doxorubicin and rituximab. These two classes of epigenetic inhibitors achieved sensitization by disrupting DNA
repair, cell cycle, and apoptotic signaling. The data used to perform these analyses are easily browsable through our
Results Explorer. Additionally, we showed that these inhibitors achieve sensitization at lower doses than those
required to induce cytotoxicity.
Conclusions: Our drug screening approach provides a systematic framework to test non-simultaneous drug
combinations. This methodology identified HDAC and HMT inhibitors as successful sensitizing compounds in
treatment-resistant DLBCL. Further investigation into the mechanisms behind successful epigenetic sensitization
highlighted DNA repair, cell cycle, and apoptosis as the most dysregulated pathways. Altogether, our method adds
supporting evidence in the use of epigenetic inhibitors as sensitizing agents in clinical settings.
Keywords: Epigenetic reprogramming, High-throughput drug screening, epigenetic inhibitors, Drug resistance in
cancer, DLBCL
Background
DNA methylation and histone modifications dynamically
regulate the chromatin structure, playing an important
role in defining and maintaining cells’ identity [1]. Epige-
nome disruption has also been linked to several diseases
including cancer [2–4] and causing treatment failure [5].
Inhibitors of enzymes responsible for writing, reading,
and erasing epigenetic marks can be used as cytotoxic
agents on tumor cells and several of them are already in
clinical trial [6]. Importantly, epigenetic compounds
have recently been shown to reprogram cellular pheno-
types, which enable a novel treatment approach that ex-
ploits the plastic nature of the epigenome to turn drug
resistant cancer cells into sensitive ones [7, 8].
Episensitization studies so far have focused on manually
testing the sensitizing potential of one or few epigenetic com-
pounds [7, 9]. To advance the episensitization experiments
to larger-scale level, we developed a novel, high-throughput
drug screening protocol to enable non-simultaneous admin-
istration of multiple compounds over a period spanning
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several days. We also created an inhibitor collection to test
all main classes of epigenetic enzymes, comprising DNA
methyltransferases (DNMTs), histone methyltransferases
(HMTs), histone acetyltransferases (HATs), histone
demethylases (HDMs), histone deacetylases (HDACs), and
bromodomains (BRDs).
We systematically assessed the ability of epigenetic in-
hibitors to overcome treatment resistance in diffuse large
B-cell lymphoma (DLBCL). The standard of care therapy
given to previously untreated DLBCL patients of all ages
and subtypes is the immunochemotherapy called R-
CHOP [10]. This combination consists of rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednis-
one and cures approximately 60% of the patients [10]. The
key compounds in R-CHOP are the topoisomerase II in-
hibitor doxorubicin and the monoclonal antibody rituxi-
mab. Doxorubicin is an anthracycline that induces DNA
damage, and its addition to the regimen increased the 10-
year overall survival of 20% [11, 12]. Rituximab targets the
B-cell surface protein CD20, and both activate immune
response and induce apoptosis via p38 MAP-kinase sig-
naling pathway [13, 14]. Addition of rituximab to CHOP
increased the 5-year overall survival by 10% [15–19]. Even
though several genes, such as TP53, STAT3/6, CDKN2A,
and EZH2, have been suggested to confer resistance to R-
CHOP [20, 21], there is no clinically effective treatment
available for resistant patients. Given that DLBCL is the
most common aggressive lymphoid cancer [22] and that
patients who are not cured with R-CHOP have dismal
prognosis, novel strategies to overcome R-CHOP resist-
ance are urgently needed.
Our observations from screening 60 epigenetic inhibitors
in four DLBCL cell lines revealed HDAC and HMT inhibi-
tors as particularly effective in sensitizing these cell lines to
doxorubicin and rituximab. Our results further show that
epigenetic sensitization is achieved at lower doses than epi-
genetic cytotoxicity, potentially causing less severe side ef-
fects in clinical settings. Thus, the herein identified
inhibitors are clinically promising candidates for combin-
ation treatment of resistant of refractory DLBCL patients.
To further describe mechanisms involved in the effect-
iveness of epigenetic compounds, we generated tran-
scriptome sequencing and immunofluorescence data
from DLBCL cell lines before and after treatment. Ana-
lyses of these data highlighted dysregulation of DNA re-
pair as a key mechanism for episensitization. To
facilitate exploiting our data and results, we have imple-
mented an interactive Results Explorer tool (http://app.
anduril.org/DLBCL_DSRT).
Results
High-throughput multi-step drug combination screening
To systematically investigate the reprogramming ability
of multiple epigenetic compounds, we have designed a
high-throughput screening protocol that uses automated
liquid handling to pretreat suspension cells with epigen-
etic inhibitors before exposing them to doxorubicin and
rituximab, as representatives of standard treatment. The
protocol comprises three main steps. First, cells are
seeded on two replicate sets of microplates with previ-
ously administered reprogramming compounds. A 10,
000-fold concentration range is used to test each epigen-
etic inhibitor, to determine the optimal dose inducing
sensitization. Second, cells are incubated with the com-
pounds for either 1 or 3 days (pilot experiment, Add-
itional file 1: Figure S1), or for 9 days using on-plate
passaging protocol (Fig. 1). This allows estimation of the
time needed by each compound to induce cellular
reprogramming.
The 9-day pretreatment is too long for cells to survive
without fresh media. Thus, we developed a robotic-based
protocol for on-plate cell passaging. After pretreatment,
one plate set is treated with rituximab and doxorubicin
while keeping another pretreated plate set as control.
Third, we measured cell viability and estimated the
sensitization induced by each compound using a repro-
gramming score, i.e., the maximum difference in cell via-
bility between the effect of the epigenetic inhibitor alone
and the effect of the epigenetic inhibitor followed by ad-
ministration of rituximab and doxorubicin.
Epigenetic inhibitors sensitize DLBCL cell lines to
doxorubicin and rituximab
We applied the screening protocol to investigate
whether epigenetic inhibitors are able to sensitize four
DLBCL cell lines (Oci-Ly-3, Riva-I, Su-Dhl-4, and Oci-
Ly-19) to doxorubicin and rituximab. We first con-
ducted a pilot screening using short pretreatment times
up to 3 days (described in the Additional file 1: Figure
S3). This pilot experiment indicated that increasing the
length of the pretreatment window enhances the repro-
gramming ability of epigenetic inhibitors. Thus, we in-
creased the pretreatment time to 9 days in the main
drug screening assay.
With the 9-day reprogramming, HDAC inhibitors sen-
sitized all cell lines (Fig. 2c), while BRD and HMT inhib-
itors induced sensitization in three cell lines. Oci-Ly-3
cells were the most responsive, with 20 out of the 60
epigenetic inhibitors able to sensitize to doxorubicin and
rituximab. Oci-Ly-19 and Su-Dhl-4 cells were sensitized
by nine and 10 inhibitors, respectively. Riva-I was the
most resistant cell line and was reprogrammed only by
three inhibitors. Varying response to the inhibitors was
expected due to heterogenous nature of DLBCL and be-
cause compounds such as HDAC inhibitors are known
to have different efficacy depending on cancer type and
dosage [23]. The optimal concentration at which each
compound induced reprogramming was always lower
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than the concentration at which the same compound
would induce cytotoxicity. Dose response curves are
available in the Results Explorer.
Epigenetic reprogramming acts synergistically with
rituximab and doxorubicin
We conducted a drug synergy assay to validate the
observed reprogramming effect of the 10 most potent
inhibitors. Compounds with three or more hits, i.e.,
belinostat, entinostat, and I-BET151, were tested for
synergy in all four cell lines, whereas the other com-
pounds were administered only to those cell lines
they reprogrammed in the screening. This validation
assay followed the design shown in Fig. 1, but varying
concentrations of the epigenetic inhibitors, as well as
of rituximab and doxorubicin, were now used (see
Additional file 1 and Additional file 2: Table S1).
The synergy plots are available through the Results Ex-
plorer, while Fig. 3 summarizes the synergy scores. A
score close to zero indicates that the killing effect of an
inhibitor is independent from the killing effect of doxo-
rubicin and rituximab, whereas a high score indicates a
synergistic effect [24]. None of the compounds showed
high negative scores, which indicates lack of antagonistic
effects. The highest synergy scores were observed in
compounds targeting HDACs (vorinostat, entinostat,
resminostat, belinostat) or HMTs (pinometostat, taze-
metostat, SGC0946). The most potent sensitization ef-
fects were induced by the entinostat and tazemetostat.
Inhibition of BRDs showed lower synergy.
This validation experiment confirmed the findings in
the original screen: Oci-Ly-3 cells were the most respon-
sive to reprogramming, and HDAC and HMT inhibitors
sensitized them to rituximab and doxorubicin. Su-Dhl-4
and Oci-Ly-19 cells responded to more than one syner-
gistic inhibitor, whereas belinostat was the only com-
pound synergistically reprogramming Riva-I cells.
Epigenetic sensitization to doxorubicin is achieved
through reprogramming of DNA repair mechanisms
Enhanced DNA repair is one of the key resistance
mechanisms for doxorubicin [25], so we hypothe-
sized that the observed sensitization might be due to
impaired repair. Immunofluorescence imaging of
cCasp3, gH2Ax, and RAD51 is a well-established and
quantitative approach for assaying DNA repair:
cCasp3 is an early and specific indicator of apop-
tosis, gH2Ax measures the amount of DNA damage,
and RAD51 indicates that homologous recombin-
ation is actively repairing DNA. Hence, we used im-
munofluorescence imaging of these three proteins
(Fig. 4a) to investigate DNA repair pathways affected
by entinostat, tazemetostat, belinostat, and vorinostat
(which showed high synergy with doxorubicin and
rituximab). Of note, these compounds are also clin-
ically relevant as belinostat and vorinostat received
FDA-approval for the treatment of patients with re-
lapsed or refractory peripheral T-cell lymphoma and
cutaneous T-cell lymphoma, while entinostat and
tazemetostat have obtained FDA “Breakthrough” and
“Fast Track” designations, respectively.
Cells treated with the HDAC inhibitors (entinostat,
belinostat, vorinostat) showed reduced RAD51 foci for-
mation (Additional file 1: Figure S4), suggesting im-
paired homologous recombination (HR). Non-
homologous end joining (NHEJ) was upregulated in
cells treated with HDAC inhibitors, which was expected
as NHEJ is often seen as a compensatory effect for
Fig. 1 Pretreatment screening protocol to test the reprogramming activity of multiple compounds. The protocol is developed to flexibly test
non-simultaneous drug combinations. In our experimental design, this included pretreatment with 60 epigenetic inhibitors, followed by
treatment with rituximab and doxorubicin, the major constituents in the R-CHOP combination therapy. At day 0, cells are seeded on microplates
precoated with the pretreatment compounds at five different concentrations. Cells are then passaged in the plate every third day using
automated liquid handling, including the corresponding pretreatment compound in the culture media. After 9 days of pretreatment, cells are
treated with a fixed concentration of doxorubicin and rituximab to compare the activity of the pretreatment alone (pink dose-response curve) vs.
the activity in combination with the standard treatment (purple dose-response curve)
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impaired HR. Cells treated with the HMT inhibitor
tazemetostat did not show significant effect on DNA
repair pathways.
These results support the hypothesis that HDAC
inhibitor sensitization occurs by impairing HR repair,
as shown in Fig. 4b, c. Entinostat alone does not
Fig. 2 Results of the high-throughput multi-step drug combination screening with 9 days of epigenetic pretreatment. a An example of a
compound that induced sensitization to rituximab and doxorubicin vs. phosphate-buffered saline (PBS). The combination induced 50% growth
inhibition at 1000 nM concentration, which is not seen with monotreatment with entinostat. The main aim of this report is to identify such
sensitizising compounds. b An example of a compound that does not sensitize cells to rituximab and doxorubicin, but has a cytotoxic effect. c
Summary of the reprogramming screening hits of 60 compounds across four DLBCL cell lines. Reprogramming scores above a threshold of 30%
(see Materials and Methods) and whose dose-response curve passed quality inspection are considered as hits and marked in orange. Ten
compounds, marked in bold, were selected for the synergy assay based on their reprogramming potential and mechanisms of action. All dose
response curves are available in Results Explorer (http://app.anduril.org/DLBCL_DSRT)
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affect the number of cells positive for double strand
breaks, apoptosis, or HR, compared to the untreated
control. However, the response to doxorubicin was
strikingly different in cells treated with entinostat
compared to untreated cells. The control cells were
able to repair DNA damage due to high HR activity
(Fig. 4c, blue bar) and thus avoid apoptosis.
Transcriptomic analysis identifies disruption of DNA
repair, cell cycle, and apoptosis as potential mechanisms
behind epigenetic sensitization
To further characterize the molecular mechanisms af-
fected by the observed epigenetic sensitization, we per-
formed RNA-seq of the four cell lines before and after
treating them with belinostat, entinostat, vorinostat, and
Fig. 3 Synergy scores of the top candidate pretreatments after 9-day pretreatment. The figure shows the median scores of three replicate
experiments for each measurement where higher score (red) represents synergy with doxorubicin and rituximab, and lower score (green)
antagonism. For example, entinostat shows high synergy in all cell lines except Riva-I, whereas belinostat has the highest synergetic killing effect
in Riva-I but less so in the other cells lines. Grey boxes represent untested combinations
Fig. 4 Effect of doxorubicin treatment in Oci-Ly-19 after entinostat treatment on DNA repair mechanisms quantified by immunofluorescence
assay. a Schematic representation of the experimental procedure prior immunofluorescence staining. Cell lines were treated with epigenetic
inhibitors (i.e., entinostat, belinostat, vorinostat, or tazemetostat) at days 0, 3, 6, and 9, while a copy was kept untreated as control. After 9 days,
both treated and control cell lines either received no doxorubicin or were exposed to doxorubicin for 4 and 24 h. Cells were then stained using
immunofluorescent antibodies and imaged. Cells not receiving any treatment served as negative control, while cells not pretreated with
epigenetic inhibitors but treated with doxorubicin served as positive control. b Immunofluorescence images of doxorubicin treated cells after
entinostat treatment (above) and untreated (below). Composite image includes also DAPI (blue). c Quantification of proportion of cells positive
for each marker in each image. The markers shown quantify apoptosis (cCasp3), DNA damage (gH2Ax), and homologous recombination (RAD51)
(see Methods). Entinostat-induced sensitization to exogenous DNA damage is detected as reduced RAD51 foci, increased cCasp3 positivity and
increased gamma-H2AX positivity in doxorubicin-treated cells. Asterisks indicate significant regulation (p < 0.05). All measurements from the
immunofluorescence assay are shown in Additional file 1: Figure S4
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tazemetostat (Additional file 1: Figure S5A). Differentially
expressed genes (DEGs) between treated and untreated
cells are shown in Additional file 1: Figure S5 B-E, and
can be browsed in the Results Explorer. Gene expression
landscape across cell lines and treatment conditions is
shown in Additional file 1: Figure S6.
We used DEGs from each successfully reprogrammed
combination and performed pathway enrichment ana-
lysis to explore the reprogramming mechanisms. An
overview of the top pathways identified using WikiPath-
ways database is shown in Fig. 5. All pathway results in-
cluding p values and pathway-specific DEGs for KEGG,
Reactome, and WikiPathways are provided in Additional
file 3: Table S2. All sensitized combinations showed
changes in immune response mechanisms. This was ex-
pected since DLBCL originates from B-cells, which pro-
duce antibodies in the adaptive immune system [26].
Our analysis further revealed the major histocompatibil-
ity complex (Additional file 3: Table S2) as one of the
pathways most affected by HDAC inhibitors, which is in
line with a study by Eckschlager and colleagues [23].
DNA damage and repair mechanisms were dysregu-
lated in Su-Dhl-4 and Oci-Ly-19 cells treated with
entinostat, as well as in Su-Dhl-4 cells treated with
tazemetostat. When comparing untreated and treated
conditions for all successfully sensitized cell line and
inhibitor combinations, we identified DEGs belonging
to HR, NHEJ, and other DNA repair pathways (Add-
itional file 4: Table S3). While DEGs involved in NHEJ
were identified only in Su-Dhl-4 cells treated with
entinostat, HR genes were differentially expressed
both in Su-Dhl-4 cells treated with entinostat and
tazemetostat, as well as in Oci-Ly-19 cells treated with
entinostat and vorinostat. In particular, these combi-
nations showed downregulation of XRCC2 and POLQ.
XRCC2 is essential for the proper functioning of HR
[27], and knockdown of POLQ in HR-deficient tumors
enhances cell death [28]. Thus, decreased expression
of both genes may contribute to the sensitization of
doxorubicin-resistant DLBCLs. Additionally, Su-Dhl-4
cells treated with entinostat or tazemetostat also
showed downregulation of RAD51, RAD54L, BRCA2,
and three Fanconi anemia genes (FANCA, FANCB,
and FANCM). BRCA1 expression was suppressed in
Su-Dhl-4 cells in response to entinostat. In Riva-I
cells, belinostat-induced differential expression did
not have an impact on the expression of any HR gene,
making it the only cell line reprogrammed by inhib-
ition of HDACs and not showing transcriptional
changes in DNA repair.
Disruption of cell cycle and DNA replication were also
mechanisms identified in several sensitized combinations
Fig. 5 Summary of pathway analysis results for all cell lines and conditions. Columns represent the cell line–treatment combination (untreated
conditions are marked in blue). Sensitizing combinations are marked by an asterisk. The rows include the top pathways identified from
WikiPathways database. All pathway analysis results are available in Additional file 3: Table S2
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(i.e., Su-Dhl-4 and Oci-Ly-19 cells treated with entino-
stat, and Su-Dhl-4 cells treated with tazemetostat). In
particular, treatment of Su-Dhl-4 cells with entinostat led
to upregulation of CDKN1A, an HDAC inhibitor mechan-
ism previously suggested to induce cell cycle arrest [23].
Other pathways identified in our analysis included cell
adhesion (altered in all sensitized combinations except
Riva-I cells treated with belinostat) and TGF-β signaling
(disrupted in Oci-Ly-19 cells treated with either entinostat
or vorinostat, and in Su-Dhl-4 cells treated with entinostat).
Death receptors and ligands belonging to the TNF and
TNF-receptor superfamilies were differentially expressed in
all sensitized combinations. Indeed, HDAC inhibitors have
been demonstrated to affect apoptosis through dysregula-
tion of such protein families [23]. Pathway analysis also
showed disruption of the apoptotic pathway in Riva-I cells
treated with belinostat (Additional file 3: Table S2).
Whole exome-sequencing suggests genomic variants
relevant to drug response
To analyze the genomic variants of the cell lines, we per-
formed whole exome sequencing. We decided to pro-
duce sequencing data directly from our cells to avoid
bias due to genetic evolution of the cell lines [29]. This
analysis identified somatic mutations and known germ-
line single nucleotide polymorphisms (SNPs) that could
influence drug response or the synergistic effect of epi-
genetic sensitizing compounds used in combination with
doxorubicin and rituximab (Additional file 5: Table S4).
Among epigenetic genes, EZH2 was found mutated
(p.Y590S, missense mutation) in Su-Dhl-4, the cell line
responding to the EZH2 inhibitor tazemetostat. Interest-
ingly, this mutation has been reported to increase sensi-
tivity to EZH2 inhibitors [30]. We also observed a
truncating mutation (p.R1322X) in CREBBP, impairing
histone acetylation, and transcriptional regulation of its
targets [31] was shared in Riva-I and Oci-Ly-19 (subclo-
nal). Truncation of CREBBP is acquired in relapsed
acute lymphocytic leukemia [31], further supporting its
important role in mediating chemotherapy resistance in
lymphoid malignancies. In the same gene category, we
observed a truncating mutation in the ARID1A gene
(p.Q474X) of Riva-I cells. ARID1A was previously re-
ported to encode for a critical transcription factor in the
absence of HDAC6 [32]. It is also the most commonly
mutated and functionally disrupted component of the
tumor suppressor chromatin remodeling SWI/SNF com-
plex and thereby has been reported as an important epi-
genetic modulator [33] and contributor to genetic and
genomic instability and response to DNA damaging
agents [34].
All our cell lines harbor at least one potentially func-
tional mutation in genes encoding epigenetic enzymes
targeted in this study or in genes potentially contribut-
ing to response to epigenetic inhibitory drugs reported
in other studies. Notably, the majority of these genes
are among the most recurrently altered drivers in
DLBCL (MYD88 in 18%, CREBBP, ARID1A, and TP53
in 10%, and EZH2 in 6% of patients) [35]. A compre-
hensive genomic profiling of the cell lines is reported in
the Additional file 1.
Increased CD20 expression does not sensitize all cell lines
to rituximab
Next, we investigated whether rituximab sensitization in
response to epigenetic modifiers resulted from increased
expression of the MS4A1 gene encoding for CD20. All
four untreated cell lines express MS4A1 (with Oci-Ly-19
showing the lowest expression), but none of the four
tested epigenetic compounds was able to upregulate
MS4A1 expression. However, CD40, a key effector of
CD20 on B cells [36], was inhibited in Oci-Ly-19 cells in
response to vorinostat or tazemetostat.
We also examined if sensitization to rituximab could
be due to increased expression of CD20 on the cell sur-
face. Two compounds shown to support CD20 transport
to the cell membrane were tested using our high-
throughput screening (Additional file 1: Figure S7). Ri-
fampicin, an antibiotic shown to restore efficacy of anti-
CD20 antibodies [37], was successful only on Oci-Ly-19
cells. Suramin, a small molecule that inhibits CD40, sen-
sitized the rest of the cell lines. However, since this
sensitization was observed at different pretreatment
times for different cell lines, we cannot conclude that
upregulation of CD20 expression is required for
sensitization to rituximab.
When comparing the expression of rituximab-related
genes [38] across untreated cell lines, we observed that
Oci-Ly-3 presented a unique transcriptomic profile. Spe-
cifically, Oci-Ly-3 was the only cell line showing overex-
pression of CXCL13, a B cell-attracting chemokine [39],
and downregulation of CD27, a proapoptotic gene previ-
ously shown to link HDACs activation and cell cycle ar-
rest [40].
Discussion
Finding effective treatment options for relapsed and re-
fractory malignancies is a major challenge in cancer
therapy. Due to the plasticity of the epigenome, epigen-
etic inhibitors are a particularly interesting class of com-
pounds to sensitize cancer cells to standard therapeutic
options [41]. Hence, we designed a high-throughput ex-
perimental protocol that allows identifying epigenetic in-
hibitors able to (re)sensitize cancer cells to standard
therapeutic agents. This approach is a major step to-
wards finding clinically useful and effective drug combi-
nations. Moreover, the customizable plate layout and the
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ability to vary experiment duration by on-plate cell pas-
saging make this protocol suitable for testing multi-step
delivery for other drug combinations.
As a case study, we tested our protocol on DLBCL cell
lines that represent the heterogeneity of the disease. We
demonstrated how this experimental approach helped to
systematically evaluate the sensitization power of 60 epi-
genetic inhibitors. Our results indicate that most of
these inhibitors require several days to effectively induce
reprogramming. Only a few compounds, mainly HDAC
inhibitors, were able to sensitize cell lines within 1 and 3
days of pretreatment. Increasing the pretreatment length
allowed us to identify additional actionable mechanisms
that would be missed with a shorter assay. For instance,
DNMT inhibitors are expected to be slow acting, since
passive demethylation requires several cell cycles. Pairing
9 days of pretreatment time with multiple doses of epi-
genetic inhibitors sensitized all cell lines to doxorubicin
and rituximab, the key compounds of R-CHOP. This
suggests that epigenetic reprogramming is an effective
option across all molecular subtypes in DLBCL.
Importantly, this study demonstrates that epigenetic
drugs induced sensitization at much lower doses than
those required for cytotoxicity, suggesting that when
epigenetic drugs are used to sensitize rather than kill
cancer cells, they are likely to cause less severe side-
effects. Based on the tested pretreatment times, we
propose that epigenetic inhibitors should be adminis-
tered in a reprogramming mode, i.e., several doses
and days before chemotherapy, rather than simultan-
eously with chemotherapy.
In this study, HDAC inhibitors belinostat, entino-
stat, vorinostat, and resminostat, as well as HMT in-
hibitors tazemetostat, pinometostat, and SGC0946,
were the most potent epigenetic drugs to sensitize
cancer cells to doxorubicin and rituximab. Both clas-
ses of inhibitors are reported to be well-tolerated in
clinical trials [23, 42, 43]. Further pre-clinical investi-
gation of their reprogramming potential to identify
the correct time and dose for epigenetic sensitization
will broaden the use of these inhibitors as pretreat-
ment options on chemo-resistant cancers.
This protocol allowed to identify the right dose and pre-
treatment length for multiple epigenetic inhibitors. We then
used these parameters to investigate the mechanisms behind
epigenetic reprogramming through transcriptome analysis.
Each cell line achieved reprogramming through a different
combination of altered pathways, but we identified dysregu-
lation of DNA repair (especially HR), disruption of cell cycle,
and effects on apoptosis as the main drivers of sensitization.
This adds on previous observations on the mode of action
of HDAC and HMT inhibitors [23, 44]. Resistance to DNA
damaging agents, such as doxorubicin [45], has often been
associated with upregulation of HR-mediated DNA repair.
Our results show that belinostat, entinostat, vorinostat, and
tazemetostat can sensitize DLBCL cells via disruption of the
HR pathway. Further, sensitization by these inhibitors af-
fected the expression of several DNA repair genes, such as
XRCC2 and POLQ, both downregulated in most sensitized
combinations. These findings argue that epigenetic inhibi-
tors could also revert resistance to a wider class of DNA
damaging agents, such as platinum-based regimens and
radiotherapy.
Belinostat, as the broadest pan-HDAC inhibitor in our
collection, sensitized cells with very low evidence of HR
dysregulation but strong truncation of ARID1A tran-
scription factor, critical for the cell’s survival in the ab-
sence of HDAC6 [32]. In depth analysis of pan-HDAC
effects on a different cell line cohort might highlight al-
ternative mechanisms of action, such as disruption of
apoptosis observed in belinostat-treated Riva-I.
Even though we found a clear link between epigenetic
modifiers and sensitization to doxorubicin, we were un-
able to find the same for rituximab. The major reasons
are the undefined mechanisms of action of CD20 and
the absence of known regulatory pathways modulating
this protein.
Through the genomic characterization of our cell lines,
we were able to highlight commonly mutated genes
among DLBCL patients [35] with functional and clinical
relevance. This opens a line of pre-clinical biomarker in-
vestigation for future personalized sensitization therapy.
The most striking mutation was identified on gene
EZH2 in the GCB cell line Su-Dhl-4, the best responder
to EZH2-inhibitor tazemetostat. This EZH2 inhibitor
has the highest efficacy in EZH2-mutated DLBCL pa-
tients belonging to the GCB subtype [46], and the muta-
tion found in Su-Dhl-4 cells has been reported as a
potential biomarker for response to EZH2 inhibitors
[47]. Moreover, we observed high tazemetostat-driven
dysregulation of cell cycle genes in these cells, poten-
tially causing cell cycle arrest, a mechanism suggested by
Knutson et al. [44]. Altogether, these results suggest that
R-CHOP resistant DLBCL patients with EZH2 muta-
tions could benefit from tazemetostat pretreatment
followed by R-CHOP re-challenge.
Our study has some limitations. First, when we created
the compound library, only few HDM and HAT inhibi-
tors were available. In our experiments, these com-
pounds were not able to induce reprogramming, but
testing a more extensive inhibitor collection might iden-
tify reprogramming mechanisms targeting HDM and
HAT enzymes. Second, even though all DLBCL subtypes
were represented in our study, the number of cell lines
included was just enough to show the value of the pro-
posed protocol but relatively small to propose clinical
strategies or biomarkers with high confidence. Future
studies can however use this protocol and increase the
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number of samples and drugs. Third, since our readout
was cytotoxicity and not tumor immunity, the impact of
tumor microenvironment could not be tested in this
model; hence, the observed epigenetic reprogramming of
rituximab resistance may be only partially detected.
Fourth, some HDAC inhibitors have been shown to have
off-target effects [48], which cannot be separated from the
on-target effects in the transcriptomic analyses due to the
experimental design we have employed. Such pleiotropic
effects, however, do not impact our combination therapy
results herein but may pose challenges for tolerability of
the combination treatment and identification of specific
biomarkers in future studies. Last, even though our results
suggest that epigenetic inhibitors can be useful in a clinical
setting, a more detailed analysis is needed to estimate op-
timal dose and treatment duration in vivo.
Conclusions
Taken together, in this contribution we report a novel
methodology to screen sensitization effect of non-
simultaneous drug combinations. It is also among the
few studies investigating the use of epigenetic drugs as
sensitizing agents, instead of using them as mono- or
combination therapy, and it is the first to do so in a
systematic and high-throughput manner. The applica-
tion of this method to overcome R-CHOP resistance
further supports the use of epigenetic reprogramming
in sensitizing DLBCL to standard immunochemother-
apy combinations.
Materials and methods
An overview of the main materials and methods is reported
below. For a detailed description of experimental protocols
and bioinformatic pipelines, see the Additional file 1.
Compound collection
We curated the compound library by manually search-
ing literature and providers for compounds inhibiting
epigenetic enzymes. We collected both FDA-approved
compounds and probes targeting DNMT (n = 7),
HDAC (n = 21), HAT (n = 1), HMT (n = 15), HDM (n
= 3), and BRD (n = 13). The full list of compounds used
in each experiment is available in Fig. 2 and Additional
file 1: Figure S3, while concentration ranges are listed
in Additional file 2: Table S1.
Cell lines
We performed our epigenetic screening on four DLBCL
cell lines, representative of all DLBCL subtypes [49] and
with varying response to rituximab and doxorubicin
(Additional file 1: Figure S2). Su-Dhl-4 belongs to the
GCB subtype [50], Oci-Ly-3 and Riva-I to the ABC sub-
type [50], while Oci-Ly-19 is unclassified.
Screening procedure and parameters
Compounds were dissolved in DMSO and added to the
assay plates using a Labcyte Echo 550 acoustic dispenser.
The highest dose concentration was as advised by the
supplier followed by four tenfold dilutions.
Plate layout design included randomized positive (ben-
zethonium chloride, BzCl, Sigma-Aldrich) and negative
(DMSO, Sigma-Aldrich) controls. Compound plates were
stored under inert nitrogen gas in StoragePods (Roylan De-
velopments) until needed. Cells were seeded using BioTek
MultiFlo FX Random Access Dispenser, at 3000 cells/well
(Riva-I, Su-Dhl-4, Oci-Ly-19) or 4000 cells/well (Oci-Ly-3)
in 25 μL (1 and 3 days of pretreatment time) or 40 μL (9
days of pretreatment time). Cell plates were incubated in a
Thermo Scientific Cytomat 10C incubator at 37°C and 5%
CO2. Plates undergoing 9 days of pretreatment had a Lab-
cyte microclime lid to reduce media evaporation during the
incubation period. During the longest pretreatment time,
cells were passaged every third day (i.e. on days 3, 6, and 9)
directly in-plate with pretreatment drugs added to the new
media. Since all cell lines grew in suspension, plates were
spun down before passaging. In-plate passaging was then
performed with a Beckman Coulter Biomek FXp pipetting
device fitted with a 384 multichannel head. The BioMek
FXp protocol included the following steps:
1. Aspirate 20 μL of old media from the culture plate
(without touching the cells collected at the bottom
of the well) and discard it.
2. Aspirate 20 μL of fresh media from the plate with
drugs in media and dispense it on the cells.
3. Resuspend the cells by mixing with 20 μL volume
five times.
4. Aspirate 20 μL of old media and cells from the
culture plate and discard it.
5. Aspirate 20 μL of fresh media from the plate with
drugs in media and dispense it on the cells.
With this procedure, roughly 3/4 of the media was ex-
changed while removing half of the cells from each well.
After pretreatment, half of the plates were treated with a
fixed dose of rituximab (MabThera, diluted in phosphate-
buffered saline (PBS). Roche) and doxorubicin (diluted in
PBS. Sigma-Aldrich), while the other half received only
PBS as control. The concentrations of rituximab and
doxorubicin were determined through a drug combination
assay and are listed in Additional file 2: Table S1. After
treatment, cells were incubated for 48 h. Finally, cell viabil-
ity was measured with Promega CellTiter-Glo reagent and
BMG LABTECH FLUOstar Omega plate reader.
Analysis of DNA damage, DNA repair, and apoptosis
We used an immunofluorescence assay to measure
doxorubicin-induced DNA damage as double-strand
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breaks (detected as γH2Ax foci), efficiency of DNA re-
pair via homologous recombination (detected as RAD51
foci) and non-homologous end joining (detected 53BP1
foci), and apoptosis (detected as cleaved-Casp3). Mea-
surements obtained from untreated cells were compared
with those from cells pretreated with belinostat, entino-
stat, vorinostat, or tazemetostat.
Whole exome and RNA sequencing
All untreated cell lines were analyzed by whole exome se-
quencing to identify mutations linked to epigenetic
sensitization. We also performed RNA sequencing for the
four cell lines untreated, as well as treated with belinostat,
entinostat, vorinostat, or tazemetostat, to identify tran-
scriptomic changes induced by epigenetic reprogramming
(see Additional files 1 and 6).
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13148-019-0781-3.
Additional file 1. Supplementary file containing additional methods
and results, as well as the user guide for the Results Explorer.
Additional file 2: Table S1. Reprogramming scores and compound
concentrations.
Additional file 3: Table S2. EnrichR DEGs pathway analysis results.
Additional file 4: Table S3. DNA repair DEGs.
Additional file 5: Table S4. Exome sequencing selected variants.
Additional file 6: Table S5. Drug targets.
Additional file 7: Table S6. Gene sets preloaded in the results browser.
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